AI Terminal
Evonik Industries AG
M&A Activity • Mar 4, 2019
150_rns_2019-03-04_a9443365-a065-49ee-9384-6c7a7b8c4187.html
M&A Activity
Open in ViewerOpens in native device viewer
News Details
Ad-hoc | 4 March 2019 22:36
Evonik Industries AG: Evonik agrees to sell its Methacrylates business to Advent International for EUR3 billion
Evonik Industries AG / Key word(s): Disposal
Evonik Industries AG: Evonik agrees to sell its Methacrylates business to Advent International for EUR3 billion
04-March-2019 / 22:36 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Evonik has today signed an agreement to sell its Methacrylates business to Advent International for EUR3 billion. The selling price (enterprise value) is 8.5 times the business’ EBITDA. The transaction is subject to approval by the authorities in several countries and is expected to close in the third quarter of this year.
The Methacrylates business has 18 production sites and 3,900 employees worldwide. From 2016 to 2018, the business generated an average annual EBITDA of about EUR350 million and sales of about EUR1.8 billion per year. For 2019 Evonik expects sales and EBITDA at a similar level.
The transaction comprises the Methacrylates, Acrylic Products and CyPlus business lines, and some of the methacrylate resins activities. Evonik put these operations on the market as part of its systematic strategy of sharpening its focus on specialty chemicals, which are less cyclical.
The net purchase price (equity value) can be calculated after deductions, made up primarily of pension obligations of around EUR500 million. Evonik will use the sale proceeds to strengthen its balance sheet and, above all, for targeted growth projects. That includes funding the purchase price of the US company PeroxyChem, which Evonik plans to close this year. In addition, some funds will be used to strengthen the present specialty chemicals portfolio, for example, by building a new polyamide
12 plant in Marl, Germany. These businesses generate an attractive margin and an above-average cash flow. Also in 2019 and even without the contribution from the Methacrylates business, Evonik will be able to cover the dividend payment out of its free cash flow.
The key financial figure “EBITDA” used in this notification means the adjusted EBITDA of the Group as allocated to the methacrylates business and adjusted to a stand alone view of the business.
For additional information on the performance measure “adjusted EBITDA” of the group please refer to pages 173 f. of the Financial Report 2017 of Evonik Industries AG. The Financial Report 2017 is available under: https://corporate.evonik.de/Downloads/Corporate/BPK/Evonik_FB2017_E.pdf.
Contact/Person making the notification:
Tim Lange
Head of Investor Relations
+49 201 177-3150
04-March-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
| Language: | English |
| Company: | Evonik Industries AG |
| Rellinghauser Straße 1-11 | |
| 45128 Essen | |
| Germany | |
| Phone: | +49 (0) 201 177-01 |
| Fax: | +49 (0) 201 177-3475 |
| E-mail: | [email protected] |
| Internet: | www.evonik.com |
| ISIN: | DE000EVNK013 |
| WKN: | EVNK01 |
| Indices: | MDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Luxembourg Stock Exchange |
| End of Announcement | DGAP News Service |